Researchers at Cellectis leveraged gene editing to create a CAR T cell that acts in an IF/THEN system. Traditional methods to develop CAR T cells that use the patient’s cells introduce challenges ...

Chimeric antigen receptor (CAR) T-cell therapy has had a transformational impact on the treatment of aggressive hematologic ...

Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the ...

What factors contribute to treatment resistance in chimeric antigen receptor (CAR)-T cell therapy treatments for solid tumors? While CAR-T therapy treatments have proven effective in patients with ...

While CAR-T therapies could vastly improve outcomes in some types of blood cancer, finding ways to replicate this effectively and safely in solid tumours remains a challenge. But a conference in ...

Scientists push CAR T cell therapy beyond blood cancers, unlocking potential for targeting solid tumors with enhanced delivery, resilience, and precision in the face of tough obstacles.

Preliminary findings from the phase 1 trial showed that GCC19CART, a novel CAR T-cell therapy, demonstrated clinical ...

"Unlike most drugs, CAR-T cell products are not uniform ... programs should also be explored further, especially in solid tumor contexts, where exhaustion plays a large part in limiting anti ...

CAR-T therapies have transformed the treatment of various blood cancers, but have been less effective for solid tumours, in part because they find it difficult to target cancer cells, as well as ...

We need to understand what's happening at the molecular level so we can engineer CAR T cells to adapt their killing behavior to target hard-to-treat malignancies, such as solid tumors." ...

Abstract Title: Clinical results of a phase 1 trial evaluating a HER2 directed CAR-T product selective for the tumor microenvironment (TME) in patients with GI and other solid tumor malignancies ...